SCH66336: a Phase II randomised, open-label study of SCH66336 and an Active Reference Agent Gemcitabine in Patients with Metastic Adenocarcinoma of the Pancreas

  • Ferry, David (Principal Investigator)
  • Kerr, David (Co-Investigator)

Project Details

Short titleSCH66336: a Phase II randomised, open-label study of SCH66336 and an Active Reference Agent Gemcitabine in Patients with Metastic Adenocarcinoma of the Pancreas
StatusFinished
Effective start/end date1/03/99 → 30/09/00

Funding

  • SCHERING-PLOUGH LTD